Drug Insight: vascular disrupting agents and angiogenesis—novel approaches for drug delivery
Authors:
- Matthew M CooneyMCMatthew M Cooney
- Willem van HeeckerenWHWillem van Heeckeren
- Shyam BhaktaSBShyam Bhakta
- Jose OrtizJOJose Ortiz
- Scot C RemickSRScot C Remick
- 1 December 2006
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Oncology
- Vol. 3 (12) , 682-692
Abstract
Vascular disrupting agents (VDAs), or endothelial disrupting agents, attempt to exploit the vascular endothelium that supplies rapidly dividing neoplasms. Unlike antiangiogenesis agents (e.g. the monoclonal antibody bevacizumab; and tyrosine kinase inhibitors sorafenib and sunitinib) that disrupt endothelial cell survival mechanisms and the development of a new tumor blood supply, VDAs are designed to disrupt the already established abnormal vasculature that supports tumors, by targeting their dysmorphic endothelial cells. Tumor vascular endothelium is characterized by its increased permeability, abnormal morphology, disorganized vascular networks, and variable density. VDAs induce rapid shutdown of tumor blood supply, causing subsequent tumor death from hypoxia and nutrient deprivation. The safety profile of this class of compounds is more indicative of agents that are indeed 'vascularly' active. For example, VDAs can cause: acute coronary and other thrombophlebitic syndromes; alterations in blood pressure, heart rate, and ventricular conduction; transient flush and hot flashes; neuropathy; and tumor pain. Despite these cardiovascular concerns some patients have benefited from VDAs in early clinical trials. Further drug development of VDAs must include the combination of these agents with other novel biological agents, cytotoxic chemotherapy, and radiotherapy. Close monitoring of patients receiving VDAs for any cardiovascular toxicity is imperative.Keywords
This publication has 53 references indexed in Scilit:
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Molecular regulation of vessel maturationNature Medicine, 2003
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Tumour necrosis factor-α plasma levels after flavone acetic acid administration in man and mouseEuropean Journal of Cancer, 1993
- Vinca alkaloids: Anti-vascular effects in a murine tumourEuropean Journal of Cancer, 1993
- Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanismEuropean Journal of Cancer and Clinical Oncology, 1991
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI: Journal of the National Cancer Institute, 1990
- Vascular collapse after flavone acetic acid: A possible mechanism of its anti-tumour actionEuropean Journal of Cancer and Clinical Oncology, 1989
- Flavone acetic acid—Preclinical and clinical activityEuropean Journal of Cancer and Clinical Oncology, 1989
- Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liverCancer, 1983